Juvenile-onset spondyloarthritis: 17-year outcomes and comparison with late adult-onset disease. Results from the REGISPON-3 cohort

Rheumatology is the branch of medicine dedicated to understanding and treating conditions that cause pain, swelling, and stiffness in the joints, muscles, and bones. Among the many conditions in this field is a group of diseases known as spondyloarthritis. These are chronic inflammatory disorders where the body's immune system mistakenly attacks its own tissues, particularly along the spine and where tendons attach to bone. While these conditions often appear in adulthood, they can also begin in childhood or adolescence. When they start early, they are called juvenile-onset spondyloarthritis. For decades, doctors have viewed these childhood cases as distinct from adult cases, often focusing on the swollen joints and heel pain that children typically show. However, a critical question has lingered: does the disease change as the patient grows older? Does a child with a peripheral joint problem eventually develop the severe spinal damage seen in older adults, or does it remain a different kind of illness entirely? Understanding this long-term journey is vital because it determines how doctors monitor patients and when they should intervene to prevent permanent disability.

A team of researchers in Spain set out to answer this question by looking at a group of patients over a remarkably long period. They studied individuals whose symptoms began before they turned sixteen and followed them for seventeen years, tracking how their bodies changed, how their treatments evolved, and how their daily lives were affected. To get a clear picture, they compared these long-term survivors with a second group of people whose symptoms did not start until they were at least thirty-five years old. By examining both groups at the same point in time, the researchers could see if the age at which the disease started created a lasting difference in how the illness behaved decades later.

The study began with fifty-seven patients who had first felt symptoms around the age of twelve. When the researchers first met them, these patients were in their late thirties. After nearly two decades, the team re-evaluated them when they were in their mid-fifties. The results revealed a significant shift in the nature of the disease. While many of these patients had started with issues in their limbs, hips, or heels, the vast majority had developed severe inflammation in their spine and the joints connecting the spine to the pelvis. In fact, more than seventy percent of them now showed clear signs of structural damage on X-rays, a condition known as radiographic axial spondyloarthritis. This finding suggests that what begins as a childhood joint issue often transforms into a primary spinal disease as the patient ages.

Despite the fact that the patients' blood tests showed less inflammation over time and that more than half were taking advanced biologic medications to suppress the immune system, their physical ability to function actually declined. The researchers measured this using a standard scale for daily tasks, and the scores worsened from the first visit to the final one. This creates a complex picture: the fire of inflammation was being controlled, but the damage it had already caused—such as stiffening of the joints and fusion of the spine—remained. These structural changes are permanent and cannot be reversed by medication, leading to a gradual loss of mobility even when the disease is quiet.

When the researchers compared these childhood-onset patients to the group that developed the disease in their late thirties, distinct patterns emerged. The group that started young waited much longer to receive a correct diagnosis, often suffering for over thirteen years before a specialist identified the condition. In contrast, the late-onset group was diagnosed much faster, usually within three years. The younger group also showed a stronger link to a specific genetic marker called HLA-B27 and had a much higher rate of spinal inflammation and X-ray damage. Conversely, the group that started later in life was more likely to have skin psoriasis and swelling in the peripheral joints of the arms and legs, and they relied more heavily on older, non-biologic medications.

The study also tracked when patients began receiving the most powerful treatments available. Those who started with the disease as children began using biologic therapies significantly earlier in their disease course than those who started as adults. This suggests that doctors recognize the severity and potential for damage in the childhood-onset group more quickly once the diagnosis is made, even though the initial diagnosis itself took much longer to achieve. The researchers noted that while the two groups looked very different at the start, the long duration of the disease in the childhood group played a major role in shaping their final outcome. When the researchers adjusted their analysis to account for how long each person had been sick, some of the differences between the groups disappeared, but the higher use of biologic drugs in the childhood group remained a clear and consistent finding.

Ultimately, this long-term view challenges the idea that juvenile-onset spondyloarthritis is a separate, self-limiting childhood condition. Instead, it appears to be an early entry point into a lifelong spectrum of spinal disease that often becomes more severe and structurally damaging over time. The study highlights a troubling reality: the long delay in diagnosing these young patients may allow irreversible damage to accumulate before treatment begins. While modern medicines can control the active inflammation, they cannot undo the structural changes that occur during those lost years. The findings underscore the need for doctors to look beyond the obvious joint swelling in children and consider the possibility of spinal involvement earlier, potentially changing the trajectory of the disease before permanent disability sets in.